Literature DB >> 2967752

Regression of left ventricular hypertrophy during combined atenolol and nifedipine treatment.

I W Franz1, U Tönnesmann, U Behr, R Ketelhut.   

Abstract

36 patients with previously untreated essential hypertension and left ventricular hypertrophy were treated with a fixed dose combination of atenolol 50 mg and sustained release nifedipine 20 mg once daily for a mean period of 12.1 months. Echocardiography showed a significant decrease after a mean period of 7.9 months in interventricular septal thickness (13.6%, p less than 0.01), posterior wall thickness (12.6%, p less than 0.001) and left ventricular mass index (18.3%). After 12.1 months the reductions were 20.7% (p less than 0.001), 22.5% (p less than 0.001) and 30.8% (p less than 0.001), respectively. Posterior wall thickness was significantly reduced, but left ventricular end-systolic and end-diastolic dimensions and fractional shortening remained unchanged. Treatment significantly reduced resting blood pressure from 153/105 mm Hg to 122/79 mm Hg (p less than 0.001), and exercise blood pressure at 100W from 189/109 to 157/93 mm Hg (p less than 0.001). Thus, nifedipine in combination with atenolol produces significant blood pressure reduction accompanied by regression of left ventricular hypertrophy without noticeable changes in left ventricular function.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2967752     DOI: 10.2165/00003495-198800354-00010

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  14 in total

1.  Cardiac hypertrophy in spontaneously hypertensive rats.

Authors:  S Sen; R C Tarazi; P A Khairallah; F M Bumpus
Journal:  Circ Res       Date:  1974-11       Impact factor: 17.367

2.  Long-term effect of antihypertensive therapy on left ventricular hypertrophy.

Authors:  I W Franz; U Tönnesmann; U Behr; R Ketelhut
Journal:  J Hypertens Suppl       Date:  1987-12

3.  Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements.

Authors:  D J Sahn; A DeMaria; J Kisslo; A Weyman
Journal:  Circulation       Date:  1978-12       Impact factor: 29.690

4.  Reversal of left ventricular hypertrophy and improvement of cardiac function in man by nifedipine.

Authors:  B E Strauer; M Atef Mahmoud; F Bayer; I Bohn; U Motz
Journal:  Eur Heart J       Date:  1984-12       Impact factor: 29.983

5.  [Regression of myocardial hypertrophy in hypertensives on chronic beta-receptor block].

Authors:  I W Franz; D Wiewel; M Behr; R Ketelhut
Journal:  Dtsch Med Wochenschr       Date:  1986-04-04       Impact factor: 0.628

6.  Reversal of left ventricular hypertrophy in hypertensive patients treated with methyldopa. Lack of association with blood pressure control.

Authors:  F M Fouad; Y Nakashima; R C Tarazi; E E Salcedo
Journal:  Am J Cardiol       Date:  1982-03       Impact factor: 2.778

7.  Regression of left ventricular hypertrophy from systemic hypertension by enalapril.

Authors:  Y Nakashima; F M Fouad; R C Tarazi
Journal:  Am J Cardiol       Date:  1984-04-01       Impact factor: 2.778

8.  Effects of labetalol on left ventricular mass and function in hypertension--an assessment by serial echocardiography.

Authors:  U Kaul; J C Mohan; M L Bhatia
Journal:  Int J Cardiol       Date:  1984-04       Impact factor: 4.164

9.  Left ventricular hypertrophy regression in hypertensive patients treated with metoprolol.

Authors:  L Corea; M Bentivoglio; P Verdecchia; M Provvidenza; M Motolese
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1984-07

10.  Differential antihypertensive effect of acebutolol and hydrochlorothiazide/amiloride hydrochloride combination on elevated exercise blood pressures in hypertensive patients.

Authors:  I W Franz
Journal:  Am J Cardiol       Date:  1980-08       Impact factor: 2.778

View more
  2 in total

Review 1.  Sustained release nifedipine formulations. An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders.

Authors:  D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

2.  m6A regulator-mediated RNA methylation modification patterns are involved in immune microenvironment regulation of coronary heart disease.

Authors:  Zhaoshui Li; Yanjie Song; Meng Wang; Ruxin Shen; Kun Qin; Yu Zhang; Ting Jiang; Yifan Chi
Journal:  Front Cardiovasc Med       Date:  2022-08-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.